Key facts
- This page summarizes Harald Reinhart's Form 4 filing for Zai Lab Ltd (ZLAB).
- 8 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 03 Apr 2024, 21:45.
Harald Reinhart - 01 Apr 2024 Form 4 Insider Report for Zai Lab Ltd (ZLAB)
- Reporting relationship
- President and Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases
- Issuer ticker
- ZLAB
- Reported as of
- 01 Apr 2024
- Net transaction value
- +$44,063
- SEC form
- 4
- Accepted by SEC
- 03 Apr 2024, 21:45:08 UTC
- Prior SEC filing
- 03 Jan 2024
- Next SEC filing
- 05 Apr 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Bruce Blefeld, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Harald Reinhart filed Form 4 for Zai Lab Ltd (ZLAB) on 03 Apr 2024.
Change
- Previous filing in this sequence was filed on 03 Jan 2024.
- Current net transaction value: +$44,063.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ZLAB
transaction
American Depositary Shares
Options Exercise
- Transaction value
- $55,811
- Shares
- +3,338
- Change %
- +7.2%
- Price
- $16.72
- Shares after
- 49,398
- Date
- 01 Apr 2024
- Ownership
- Direct
- Footnotes
- F1, F2
ZLAB
transaction
American Depositary Shares
Options Exercise
- Transaction value
- $16,887
- Shares
- +1,010
- Change %
- +2%
- Price
- $16.72
- Shares after
- 50,408
- Date
- 01 Apr 2024
- Ownership
- Direct
- Footnotes
- F1, F2
ZLAB
transaction
American Depositary Shares
Sale
- Transaction value
- $21,965
- Shares
- -1,360
- Change %
- -2.7%
- Price
- $16.15
- Shares after
- 49,048
- Date
- 02 Apr 2024
- Ownership
- Direct
- Footnotes
- F1, F3
ZLAB
transaction
American Depositary Shares
Sale
- Transaction value
- $6,670
- Shares
- -413
- Change %
- -0.84%
- Price
- $16.15
- Shares after
- 48,635
- Date
- 02 Apr 2024
- Ownership
- Direct
- Footnotes
- F1, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ZLAB
transaction
Derivative
Stock Options (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +107,321
- Change %
- Price
- $0.000000
- Shares after
- 107,321
- Date
- 01 Apr 2024
- Ownership
- Direct
- Underlying class
- American Depositary Shares
- Underlying amount
- 107,321
- Exercise price
- $16.72
- Footnotes
- F1, F4, F5
ZLAB
transaction
Derivative
Restricted Share Units
Award
- Transaction value
- $0
- Shares
- +69,758
- Change %
- Price
- $0.000000
- Shares after
- 69,758
- Date
- 01 Apr 2024
- Ownership
- Direct
- Underlying class
- American Depositary Shares
- Underlying amount
- 69,758
- Exercise price
- Footnotes
- F1, F6, F7
ZLAB
transaction
Derivative
Restricted Share Units
Options Exercise
- Transaction value
- $0
- Shares
- -3,338
- Change %
- -25%
- Price
- $0.000000
- Shares after
- 10,016
- Date
- 01 Apr 2024
- Ownership
- Direct
- Underlying class
- American Depositary Shares
- Underlying amount
- 3,338
- Exercise price
- Footnotes
- F1, F6, F8
ZLAB
transaction
Derivative
Restricted Share Units
Options Exercise
- Transaction value
- $0
- Shares
- -1,010
- Change %
- -33%
- Price
- $0.000000
- Shares after
- 2,020
- Date
- 01 Apr 2024
- Ownership
- Direct
- Underlying class
- American Depositary Shares
- Underlying amount
- 1,010
- Exercise price
- Footnotes
- F1, F6, F9
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 9 footnotes
Footnote F1
Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs.
Footnote F2
ADSs acquired on vesting of Restricted Share Units.
Footnote F3
These ADSs were sold automatically to cover taxes upon vesting of Restricted Share Units.
Footnote F4
Each Stock Option is exercisable for one ADS, which represents ten Ordinary Shares of the issuer.
Footnote F5
The option vests in equal annual installments over four years beginning on 04/01/2025, the first anniversary of the date of grant, subject to continuous service.
Footnote F6
Each Restricted Share Unit ("RSU") represents a contingent right to receive one ADS, which represents ten Ordinary Shares of the issuer.
Footnote F7
The RSUs vest in equal annual installments over four years beginning on 04/01/2025, the first anniversary of the date of grant, subject to continuous service. Vested shares will be delivered to the reporting person following vesting.
Footnote F8
The RSUs vest in equal annual installments over five years beginning on 04/01/2023, the first anniversary of the date of grant. Vested shares will be delivered in the form of ADSs to the reporting person following vesting.
Footnote F9
The RSUs vest in equal annual installments over five years beginning on 04/01/2022, the first anniversary of the date of grant. Vested shares will be delivered in the form of ADSs to the reporting person following vesting.
SEC remarks
President and Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases